- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ipca Labs gets USFDA EIR for Ratlam facility
Mumbai: Ipca labs has recently announced that the Company's manufacturing facility situated at Sejavata, Ratlam, Madhya Pradesh has received United States Food and Drug Administration (USFDA)'s Establishment Inspection Report (EIR) classifying the manufacturing facility as Voluntary Action Indicated (VAI).USFDA had inspected the said facility from 5th June, 2023 to 13th June, 2023 and issued...
Mumbai: Ipca labs has recently announced that the Company's manufacturing facility situated at Sejavata, Ratlam, Madhya Pradesh has received United States Food and Drug Administration (USFDA)'s Establishment Inspection Report (EIR) classifying the manufacturing facility as Voluntary Action Indicated (VAI).
USFDA had inspected the said facility from 5th June, 2023 to 13th June, 2023 and issued Form 483 with eleven observations.
Read also: USFDA issues 11 observations to Ipca Labs Ratlam facility
Voluntary action indicated (VAI), which means objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
Ipca Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. The Company was founded by group of businessmen and medical professionals in 1949. It produces theobromine, acetyl thiophene, and p-bromotoluene as active pharmaceutical ingredients (APIs). Ipca sells these APIs and their intermediates globally. Ipca is a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments.
Read also: Hitesh Kumar Maheshwari joins Ipca Labs as President - RnD (Formulations)
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751